Marksans Pharma Limited.

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Market cap

₹15,072 cr

P/E (TTM)

29.1

P/B (latest)

5

ROE (TTM)

13.8%

ROCE (TTM)

17.6%

Sales CAGR 3y

16.8%

PAT CAGR 3y

16.2%

Debt / equity

0.01x

Promoter

43.9%

Dividend yield

0.27%

Size

Micro

Codes

MARKSANS · 524404

52-week ₹156.89 – ₹347.6 · ADTV ₹103.8 cr · price-only.